newsFirst real-world study reveals encouraging efficacy for cell therapy7 October 2024 | By Catherine Eckford (European Pharmaceutical Review)More than half of the multiple myeloma patients included in this study would have been ineligible for the Phase II CARTITUDE-1 clinical trial, research reports.
newsInnovative personalised immunotherapy approved for multiple myeloma8 April 2024 | By Catherine Eckford (European Pharmaceutical Review)Approval of the cell therapy by the US FDA could provide a treatment-free respite as early as first relapse for patients with multiple myeloma.
newsEMA human medicines committee (CHMP) meeting highlights, March 202228 March 2022 | By Hannah Balfour (European Pharmaceutical Review)The March meeting saw the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommend five medications for approval including a multiple myeloma gene therapy.
newsFDA approves Carvykti for patients with multiple myeloma1 March 2022 | By European Pharmaceutical ReviewUS FDA approval based on 98 percent response rate in multiple myeloma patients treated once with Carvykti (ciltacabtagene autoleucel, cilta-cel).
newsCilta-cel achieves progression-free survival in multiple myeloma patients15 December 2021 | By Anna Begley (European Pharmaceutical Review)In the Phase Ib/II trial, cilta-cel achieved minimal residual disease negativity in 92 percent of patients and improved survival.
newsCilta-cel induces deep and durable responses in relapsed or refractory multiple myeloma trial2 June 2021 | By Hannah Balfour (European Pharmaceutical Review)New trial data shows 98 percent of heavily pre-treated relapsed/refractory multiple myeloma patients responded to Janssen’s ciltacabtagene autoleucel (cilta-cel).
